iSTAR Medical continues to strengthen US presence with appointment of Chief Medical Officer and Vice President of Clinical Affairs
04 sept. 2024 07h00 HE
|
iSTAR Medical
For immediate release iSTAR Medical continues to strengthen US presence with appointment of Chief Medical Officer and Vice President of Clinical Affairs WAVRE, Belgium — 4 September 2024: iSTAR...
Hexiris Welcomes Dr. Paul Harasymowycz to Its Scientific Committee
02 avr. 2024 07h00 HE
|
Hexiris Inc.
DIEPPE, New Brunswick, April 02, 2024 (GLOBE NEWSWIRE) -- Hexiris Inc. (“Hexiris” or the “Company”), a medical device firm dedicated to advancing and simplifying Minimally Invasive Glaucoma Surgery...
Hexiris Pharma Welcomes World-Renowned Ophthalmologist Dr. Ike Ahmed to its Scientific Committee
30 oct. 2023 07h30 HE
|
Hexiris Inc.
DIEPPE, New Brunswick, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Hexiris Pharma Inc. (“Hexiris Pharma” or the “Company”), a pharmaceutical firm dedicated to advancing and simplifying Minimally Invasive...
Iantrek reports two upcoming American Academy of Ophthalmology presentations of its breakthrough glaucoma surgical technologies, including 1-year results of a novel supraciliary outflow micro-interventional procedure
16 oct. 2023 08h00 HE
|
Iantrek, Inc.
Biotech startup to present 12 month data for novel Glaucoma treatment at AAO.
12-month clinical results of a novel micro-interventional bio-stenting procedure published in the British Journal of Ophthalmology
23 janv. 2023 08h00 HE
|
Iantrek, Inc.
WHITE PLAINS, N.Y., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Iantrek today announced the publication of 12-month clinical results of a novel bio-stenting procedure using the company’s microsurgical...
iSTAR Medical Expands Commercial Rollout of MINIject with First Surgeries in Sweden and Norway
01 déc. 2022 03h00 HE
|
iSTAR Medical
For immediate release iSTAR Medical Expands Commercial Rollout of MINIject with First Surgeries in Sweden and Norway The only commercially available MIGS device currently targeting the supraciliary...
Iantrek Raises $23M Series B Financing to Advance Next Generation Ophthalmic Micro-Interventional Technologies
30 août 2022 08h00 HE
|
Iantrek, Inc.
WHITE PLAINS, N.Y., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Iantrek, Inc., a medical device company founded by ophthalmic innovator Dr. Sean Ianchulev, announced the closing of a $23M Series B financing....
Sight Sciences Introduces the SION™ Surgical Instrument – The First Bladeless Device Used in Goniotomy
23 août 2022 08h03 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to...
Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI® Surgical System in Patients with Open Angle Glaucoma
16 août 2022 08h01 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to...
iSTAR Medical Presents Positive Consistent Results for MINIject® Across Three International Glaucoma Trials
08 juin 2022 02h00 HE
|
iSTAR Medical
For immediate release iSTAR Medical Presents Positive Consistent Results for MINIject® Across Three International Glaucoma Trials Analysis provides further validation of MINIject®’s meaningful and...